Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;28(9):1297-1299.
doi: 10.1016/j.cmi.2022.05.002. Epub 2022 May 17.

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab

Camille Vellas  1 , Pauline Trémeaux  2 , Arnaud Del Bello  3 , Justine Latour  2 , Nicolas Jeanne  2 , Noémie Ranger  2 , Chloé Danet  4 , Guillaume Martin-Blondel  5 , Pierre Delobel  5 , Nassim Kamar  3 , Jacques Izopet  6
Affiliations

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab

Camille Vellas et al. Clin Microbiol Infect. 2022 Sep.
No abstract available

PubMed Disclaimer

References

    1. Cao Y., Wang J., Jian F., Xiao T., Song W., Yisimayi A., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–663. - PMC - PubMed
    1. Gupta A., Gonzalez-Rojas Y., Juarez E., Crespo Casal M., Moya J., Rodrigues Falci D., et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327:1236–1246. - PMC - PubMed
    1. Vellas C., Del Bello A., Debard A., Steinmeyer Z., Tribaudeau L., Ranger N., et al. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies. Clin Microbiol Infect. 2022;28:139. e5–139.e8. - PMC - PubMed
    1. Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv 2021 [Epub ahead of print].
    1. Iketani S., Liu L., Guo Y., Liu L., Chan J.F.-W., Huang Y., et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553–556. - PMC - PubMed

Supplementary concepts

LinkOut - more resources